Literature DB >> 14767470

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

Li-Fen Lee1, Maggie C Louie, Sonal J Desai, Joy Yang, Hong-Wu Chen, Christopher P Evans, Hsing-Jien Kung.   

Abstract

Interleukin-8 (IL-8), a chemokine implicated in the metastasis and angiogenesis of a variety of cancers, has been reported to be overexpressed in prostate cancer. In this study, we ascribe a new role for IL-8 in prostate cancer progression using LNCaP cells. We demonstrate that IL-8 activates the androgen receptor and confers androgen-independent growth, while serving as a potent chemotactic factor. Our evaluation of the possible signal pathways involved in androgen-independence and cell migration shows that the tyrosine kinases Src and FAK (focal adhesion kinase) are involved in IL-8-induced signaling. Pharmacological and genetic inhibitors of Src and FAK interfere with IL-8-induced cell migration, while only the Src inhibitor was able to repress androgen-independent growth. This suggests that both growth and migration depend on the activity of Src, whereas cell migration also requires the activation of FAK. Our evidence that IL-8-induced androgen-independent growth is, at least in part, due to androgen receptor activation includes (1) an inhibitor of androgen receptor activity diminishes cell growth; (2) androgen receptor transactivation potential is augmented by IL-8 and (3) androgen receptor is recruited to the promoter of prostate specific antigen (PSA) upon IL-8 treatment, based on chromatin immunoprecipitation experiments. Taken together, our data suggest that in addition to its role in metastasis and angiogenesis, IL-8 may also serve as a facilitator for androgen-independent transition of prostate cancers. To our knowledge, this is the first report about the tyrosine kinase signals and androgen receptor activation induced by IL-8 in prostate cancer cells. The observation that IL-8 mediates its growth and chemotactic effects via Src and FAK suggests the potential use for tyrosine kinase inhibitors at early stage of prostate cancer development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767470     DOI: 10.1038/sj.onc.1207344

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  65 in total

1.  PSA regulates androgen receptor expression in prostate cancer cells.

Authors:  Parmita Saxena; Marco Trerotola; Tao Wang; Jing Li; Aejaz Sayeed; Jennifer Vanoudenhove; Dave S Adams; Thomas J Fitzgerald; Dario C Altieri; Lucia R Languino
Journal:  Prostate       Date:  2011-09-28       Impact factor: 4.104

2.  Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.

Authors:  Ping Yang; Linlang Guo; Zhijian J Duan; Clifford G Tepper; Ling Xue; Xinbin Chen; Hsing-Jien Kung; Allen C Gao; June X Zou; Hong-Wu Chen
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 3.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

Review 4.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

Review 5.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 6.  Src signaling pathways in prostate cancer.

Authors:  Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

7.  Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer.

Authors:  Sharanjot Saini; Shahana Majid; Varahram Shahryari; Z Laura Tabatabai; Sumit Arora; Soichiro Yamamura; Yuichiro Tanaka; Rajvir Dahiya; Guoren Deng
Journal:  Mol Cancer Ther       Date:  2014-05-09       Impact factor: 6.261

Review 8.  Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer.

Authors:  Paul J Toren; Martin E Gleave
Journal:  Asian J Androl       Date:  2013-04-15       Impact factor: 3.285

Review 9.  Molecular mechanisms of castration-resistant prostate cancer progression.

Authors:  Smitha S Dutt; Allen C Gao
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

10.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.